Analysts see $3B potential in Sanofi-Regeneron cholesterol drug alirocumab

09/26/2013 | Reuters

Sanofi and Regeneron Pharmaceuticals' late-stage cholesterol therapy candidate alirocumab has the potential to become a blockbuster with more than $3 billion in sales, analysts said. Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Deutsche Bank analysts said peak annual sales of alirocumab could reach exceed $3 billion, and BioMedTracker, an independent research firm, predicted sales of $3.7 billion by 2023.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care